Przemyslaw W. Twardowski, M.D., and his colleagues, have published a new study in the New England Journal of Medicine, which demonstrates significant benefit of therapy with olaparib (PARP inhibitor) in patients with advanced prostate cancer who harbor certain mutations of DNA repair system and who failed standard treatments. Based on the results of that study on 5/19/2020 Food and Drug Administration (FDA) granted approval of olaparib, providing a valuable treatment option for about 25% of patients with advanced prostate cancer with certain mutations of DNA repair. These mutations can be detected by performing an analysis of a patient’s cancer specimen and sometimes also on a specialized blood test.
Thanks to the participation of Saint John’s Cancer Institute and our proactive approach to offering new treatments through novel clinical trials, TWO new bladder cancer drugs have been approved by the Food and Drug Administration (FDA). We are very proud to be part of this wonderful advancement.
Prostate cancer radiation therapy can sometimes result in the injury of nearby healthy tissue, causing unwanted side effects such as bowel dysfunction. That’s why we now offer SpaceOAR Hydrogel, an innovative device aimed at helping to maintain quality of life and minimize side effects of radiation treatment by protecting organs at risk during treatment. Learn how SpaceOAR Hydrogel can reduce the radiation dose delivered to the rectum during prostate radiation therapy.